[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353602-105":59,"doc-detail-353602-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","remote-delivery-of-cancer-genetic-testing-in-veterans-with-metastatic-prostate-cancer-a-million-veteran-program-pilot-study","Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer - A Million Veteran Program pilot study","","Remote germline testing helps guide targeted therapy for metastatic prostate cancer and supports early detection and family risk reduction, yet real-world uptake remains low. This prospective Million Veteran Program pilot study enrolled veterans with metastatic prostate cancer, using mailed opt-out procedures, follow-up contact, and consent-supported saliva kit testing via a CLIA-level multigene panel with genetic counseling. Among eligible participants, completion exceeded prior reports, revealing clinically actionable pathogenic variants.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/remote-delivery-of-cancer-genetic-testing-in-veterans-with-metastatic-prostate-cancer-a-million-veteran-program-pilot-study/353602/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/remote-delivery-of-cancer-genetic-testing-in-veterans-with-metastatic-prostate-cancer-a-million-veteran-program-pilot-study/353602.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in metastatic prostate cancer?","Question",{"text":112,"@type":113},"Guidelines recommend germline genetic testing for men with metastatic prostate cancer, but uptake is reported to be only about 10%–12%. The study evaluates a remote delivery approach to improve completion rates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was remote genetic testing delivered to eligible veterans?",{"text":117,"@type":113},"Eligible veterans were contacted by mail with an option to opt out, received study information and follow-up phone contact, and those consenting were mailed a saliva collection kit for a CLIA-level multigene cancer risk panel.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key outcomes of remote testing completion?",{"text":121,"@type":113},"Among 1952 veterans who did not opt out, 681 (35%) consented and 459 (24%) completed testing. Completion occurred at higher rates than previously reported, and a subset of completed cases carried germline pathogenic variants.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353602,1790378138,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","DOI: 10. 1002/cncr.70283  \nORIGINAL ARTICLE  \nRemote delivery of cancer genetic testing in veterans with metastatic prostate cancer: A Million Veteran Program pilot study  \nBruce Montgomery MD 1,2,3  | Julie A. Lynch MBA, RN, PhD4,5  |  \nJessica Brown BA1 | Kara N. Maxwell MD, PhD6,7 | Craig C. Teerlink PhD4,5 | Nismeta Kabilovic BS 1 | Katie Stoll MS1,8 | Julie Simon MS 1,8 | Maria Kogan BA1 | Sajida Hassan PhD2 | Stacey B. Whitbourne PhD9  | Sumitra Muralidhar PhD 10 | Martin W. Schoen MD, MPH11  | Rachel Ramoni DMD 10  |  \nJ. Michael Gaziano MD9 | Alexandra O. Sokolova MD12 |  \nHeather H. Cheng MD, PhD2,3 | Ruth Etzioni PhD3 | Colin C. Pritchard MD, PhD1,2,3, 13  \n1VA Puget Sound Health Care System, Seattle, Washington, USA 2University of Washington, Seattle, Washington, USA  \n3Fred Hutchinson Cancer Center, Seattle, Washington, USA  \n4VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA  \n5Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA 6Corporal Michael Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA  \n7Department of Medicine-Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA 8Genetic Support Foundation, Olympia, Washington, USA  \n9Department of Medicine, Million Veteran Program Coordinating Center, Veterans Affairs Healthcare System, Boston, Massachusetts, USA 10Department of Veterans Affairs, Office of Research and Development, Washington, DC, USA  \n11VA St. Louis Health Care System, St. Louis, Missouri, USA  \n12Oregon Health and Science University, Portland, Oregon, USA 13Brotman Baty Institute for Precision Medicine, Seattle, Washington, USA  \nCorrespondence  \nBruce Montgomery, VA Puget Sound HCS, 1660 S. Columbian Way, Seattle, WA 98108, USA.  \nEmail: [rbmontgo@uw.edu](rbmontgo@uw.edu)  \nFunding information  \nInstitute for Prostate Cancer Research; National Cancer Institute, Grant/Award Number: P50CA097186; Congressionally Directed Medical Research Programs, Grant/ Award Numbers: W81XWH-17-2-0043, W81XWH2220021; Prostate Cancer  \nAbstract  \nBackground: Germline pathogenic variants can inform targeted therapy for metastatic prostate cancer (mPC), and improve cancer early detection and risk reduction for family members. Guidelines recommend germline genetic testing be offered to all men with mPC, yet uptake of testing is only 10%–12%.  \nMethods: This prospective study enrolled veterans participating in the VA Million Veteran Program (MVP) with a diagnosis of mPC. Veterans were contacted by mail with option to opt-out of future contact. Eligible veterans who did not opt-out were mailed study information and received a follow-up phone call to establish interest in  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \nPublished 2026. This article is a U.S. Government work and is in the public domain in the USA. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2026;e70283.  \n[https://doi.org/10.1002/cncr.70283](https://doi.org/10.1002/cncr.70283)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 8  \nFoundation, Grant/Award Numbers:  \nChallenge Award, Young Investigator Award; US Department of Veterans Affairs, Grant/ Award Number: MVP031  \ngermline testing. Participants provided verbal consent and were mailed a saliva collection kit for a CLIA-level multigene cancer predisposition gene panel test. Results were disclosed to the patient and oncology provider. All steps were performed with genetic counseling support.  \nResults: Of 2104 eligible patients, 1952 veterans with mPC did not opt out. Of these, 681 (35%) provided cons","cbCaijynahlu6J1C","https://ap.wps.com/l/cbCaijynahlu6J1C","pdf",1212366,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What problem does the study address in metastatic prostate cancer?\",\"answer\":\"Guidelines recommend germline genetic testing for men with metastatic prostate cancer, but uptake is reported to be only about 10%–12%. The study evaluates a remote delivery approach to improve completion rates.\"},{\"question\":\"How was remote genetic testing delivered to eligible veterans?\",\"answer\":\"Eligible veterans were contacted by mail with an option to opt out, received study information and follow-up phone contact, and those consenting were mailed a saliva collection kit for a CLIA-level multigene cancer risk panel.\"},{\"question\":\"What were the key outcomes of remote testing completion?\",\"answer\":\"Among 1952 veterans who did not opt out, 681 (35%) consented and 459 (24%) completed testing. Completion occurred at higher rates than previously reported, and a subset of completed cases carried germline pathogenic variants.\"}]","Remote delivery of cancer genetic testing in veterans with metastatic prostate cancer - A Million Veteran Program pilot study | PDF",1790106273]